$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000155837020000779 Filed on February 13, 2020

Income Statement

Concept	2019 Q4	2018 Q4	2018 Q3
Revenue	$126.3M	$130.7M	$65.69M
YoY Change	-3.36%	38.74%	-24.32%
Cost Of Revenue	$11.00M	$21.50M	$4.616M
YoY Change	-48.84%	138.89%	-24.33%
Gross Profit	$115.3M	$109.2M	$61.07M
YoY Change	5.59%	28.17%	-24.32%
Gross Profit Margin	91.29%	83.56%	92.97%
Selling, General & Admin	$39.20M	$50.50M	$50.54M
YoY Change	-22.38%	-9.82%	-18.23%
% of Gross Profit	34.0%	46.25%	82.75%
Research & Development	$26.50M	$28.20M	$29.16M
YoY Change	-6.03%		-21.41%
% of Gross Profit	22.98%	25.82%	47.75%
Depreciation & Amortization	$900.0K	$1.300M	$2.400M
YoY Change	-30.77%	-75.47%	-35.14%
% of Gross Profit	0.78%	1.19%	3.93%
Operating Expenses	$65.70M	$78.70M	$79.69M
YoY Change	-16.52%	26133.33%	-20.39%
Operating Profit	$49.60M	$30.50M	-$146.6M
YoY Change	62.62%	-64.08%	655.52%
Interest Expense	-$2.000M	-$21.50M	$9.482M
YoY Change	-90.7%	100.93%	-173.5%
% of Operating Profit	-4.03%	-70.49%
Other Income/Expense, Net	-$1.735M	-$21.49M	-$5.252M
YoY Change	-91.93%
Pretax Income	$47.90M	$8.400M	-$151.8M
YoY Change	470.24%	-88.66%	369.97%
Income Tax
% Of Pretax Income
Net Earnings	$47.86M	-$15.49M	-$174.4M
YoY Change	-408.9%	-228.04%	439.79%
Net Earnings / Revenue	37.89%	-11.85%	-265.43%
Basic Earnings Per Share	$0.31
Diluted Earnings Per Share	$0.30	-$100.6K	-$1.138M
COMMON SHARES
Basic Shares Outstanding	156.8M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$177.0M	$173.2M	$161.4M
YoY Change	2.19%	-21.77%	-28.39%
Cash & Equivalents	$177.0M	$173.2M	$141.6M
Short-Term Investments		$0.00	$19.80M
Other Short-Term Assets	$12.00M	$12.40M	$21.70M
YoY Change	-3.23%	69.86%	167.9%
Inventory	$648.0K	$0.00	$100.0K
Prepaid Expenses
Receivables	$11.28M	$20.99M	$65.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$306.9M	$266.4M	$248.5M
YoY Change	15.17%	-14.49%	-20.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.43M	$7.652M	$16.20M
YoY Change	62.43%	-55.77%	-5.81%
Goodwill	$785.0K	$785.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$790.0K	$89.00K	$151.2M
YoY Change	787.64%	-99.92%	16.58%
Total Long-Term Assets	$95.90M	$65.62M	$168.2M
YoY Change	46.15%	-77.69%	-45.92%
TOTAL ASSETS
Total Short-Term Assets	$306.9M	$266.4M	$248.5M
Total Long-Term Assets	$95.90M	$65.62M	$168.2M
Total Assets	$402.7M	$332.1M	$416.7M
YoY Change	21.29%	-45.18%	-33.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.978M	$14.89M	$9.300M
YoY Change	-73.29%	-6.93%	-46.86%
Accrued Expenses	$34.60M	$53.50M	$50.00M
YoY Change	-35.33%	17.32%	19.9%
Deferred Revenue	$875.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$47.60M	$39.40M
YoY Change	-100.0%	1060.98%	795.45%
Total Short-Term Liabilities	$40.93M	$119.5M	$112.6M
YoY Change	-65.76%	81.1%	74.57%
LONG-TERM LIABILITIES
Long-Term Debt	$408.0M	$366.3M	$369.9M
YoY Change	11.38%	-7.52%	-5.61%
Other Long-Term Liabilities	$734.0K	$2.530M	$131.4M
YoY Change	-70.99%	-98.11%	-29.43%
Total Long-Term Liabilities	$734.0K	$2.530M	$501.3M
YoY Change	-70.99%	-99.52%	-13.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.93M	$119.5M	$112.6M
Total Long-Term Liabilities	$734.0K	$2.530M	$501.3M
Total Liabilities	$41.66M	$122.1M	$613.9M
YoY Change	-65.87%	-79.51%	-4.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.572B	-$1.591B
YoY Change	-1.19%
Common Stock	$1.479B	$1.395B
YoY Change	6.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$93.25M	-$196.4M	-$197.3M
YoY Change
Total Liabilities & Shareholders Equity	$402.7M	$332.1M	$416.7M
YoY Change	21.29%	-45.18%	-33.34%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$47.86M	-$15.49M	-$174.4M
YoY Change	-408.9%	-228.04%	439.79%
Depreciation, Depletion And Amortization	$900.0K	$1.300M	$2.400M
YoY Change	-30.77%	-75.47%	-35.14%
Cash From Operating Activities	$27.60M	$9.300M	-$26.60M
YoY Change	196.77%	-200.0%	-14.74%
INVESTING ACTIVITIES
Capital Expenditures	-$2.700M	-$3.300M	-$2.100M
YoY Change	-18.18%	230.0%	40.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$20.80M	$16.40M
YoY Change	-100.0%	-163.41%	-41.64%
Cash From Investing Activities	-$2.600M	$17.50M	$14.30M
YoY Change	-114.86%	-151.78%	-46.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.400M	4.900M	7.800M
YoY Change	30.61%	-19.67%	-152.35%
NET CHANGE
Cash From Operating Activities	27.60M	9.300M	-26.60M
Cash From Investing Activities	-2.600M	17.50M	14.30M
Cash From Financing Activities	6.400M	4.900M	7.800M
Net Change In Cash	31.40M	31.70M	-4.500M
YoY Change	-0.95%	-185.68%	-76.92%
FREE CASH FLOW
Cash From Operating Activities	$27.60M	$9.300M	-$26.60M
Capital Expenditures	-$2.700M	-$3.300M	-$2.100M
Free Cash Flow	$30.30M	$12.60M	-$24.50M
YoY Change	140.48%	-251.81%	-17.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157535962
CY2019Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2019Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2018Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2018Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	0
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154414691
CY2019	irwd	Transitional Services Agreement Initial Term Of Service Low End Of Range TransitionalServicesAgreementInitialTermOfServiceLowEndOfRange	P1Y
CY2019Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiability
CY2019Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiability
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-34620
CY2019	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3404176
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Summer Street
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2300
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2019	dei	City Area Code CityAreaCode	617
CY2019	dei	Local Phone Number LocalPhoneNumber	621-7722
CY2019	dei	Security12b Title Security12bTitle	Class A Common Stock, $0.001 par value
CY2019	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2019	dei	Trading Symbol TradingSymbol	IRWD
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1697372212
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	158206912
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177023000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173172000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11279000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20991000
CY2019Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	105967000
CY2018Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	59959000
CY2019Q4	us-gaap	Inventory Net InventoryNet	648000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10685000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10216000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	847000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	306852000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	266435000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	971000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6426000
CY2019Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	32597000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12429000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7652000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17743000
CY2019Q4	us-gaap	Hedging Assets Noncurrent HedgingAssetsNoncurrent	31366000
CY2018Q4	us-gaap	Hedging Assets Noncurrent HedgingAssetsNoncurrent	41020000
CY2019Q4	us-gaap	Goodwill Goodwill	785000
CY2018Q4	us-gaap	Goodwill Goodwill	785000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	89000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	9643000
CY2019Q4	us-gaap	Assets Assets	402748000
CY2018Q4	us-gaap	Assets Assets	332050000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3978000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14891000
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1509000
CY2019Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2956000
CY2018Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2963000
CY2019Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	30465000
CY2018Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	38001000
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	73000
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	252000
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	47554000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1146000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	875000
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	15739000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40929000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	119524000
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	158000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6308000
CY2019Q4	us-gaap	Hedging Liabilities Noncurrent HedgingLiabilitiesNoncurrent	24260000
CY2018Q4	us-gaap	Hedging Liabilities Noncurrent HedgingLiabilitiesNoncurrent	33763000
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	407994000
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	265601000
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	100537000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22082000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	734000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2530000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157535962
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154414691
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	158000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	154000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1478823000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1394603000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1572232000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1591128000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-196371000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402748000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	332050000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428413000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346639000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298276000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23875000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32751000
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19097000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	-3530000
CY2018	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	247000
CY2017	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	309000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115044000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101060000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88145000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	172450000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219676000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	231184000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8111000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6214000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31045000
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31310000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3620000
CY2018	us-gaap	Restructuring Charges RestructuringCharges	14715000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151794000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	308290000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	497309000
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	313639000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	120123000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-150670000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-15363000
CY2019	us-gaap	Interest Expense InterestExpense	36602000
CY2018	us-gaap	Interest Expense InterestExpense	37724000
CY2017	us-gaap	Interest Expense InterestExpense	36370000
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	2862000
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	2991000
CY2017	us-gaap	Investment Income Net InvestmentIncomeNet	2111000
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3023000
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-8743000
CY2017	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-3284000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2009000
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	514000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61180000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43476000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39552000
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	58943000
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-194146000
CY2017	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-54915000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-88222000
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-62022000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-116937000
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.38
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.27
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.37
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.58
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.42
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.14
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.85
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	156023000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152634000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148993000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-116937000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	79000
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-72000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	79000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-72000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21505000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282289000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117009000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	66716000
CY2017	irwd	Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan	26321000
CY2017	irwd	Stock Issued During Period Value Stock Award StockIssuedDuringPeriodValueStockAward	14000
CY2017	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	301000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33505000
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-72000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-116937000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	9848000
CY2018	irwd	Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan	32061000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44009000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	79000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-196371000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-196371000
CY2019	irwd	Stock Issued During Period Value Share Based Awards And Employee Stock Purchase Plan Net Of Cancellations StockIssuedDuringPeriodValueShareBasedAwardsAndEmployeeStockPurchasePlanNetOfCancellations	13601000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32331000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	92502000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Issuance Costs AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtIssuanceCosts	2092000
CY2019	irwd	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	25159000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Repurchases AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRepurchases	26959000
CY2019	us-gaap	Dividends Dividends	2609000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2019	us-gaap	Profit Loss ProfitLoss	21505000
CY2018	us-gaap	Profit Loss ProfitLoss	-282368000
CY2017	us-gaap	Profit Loss ProfitLoss	-116937000
CY2019	us-gaap	Depreciation Depreciation	5580000
CY2018	us-gaap	Depreciation Depreciation	3859000
CY2017	us-gaap	Depreciation Depreciation	6442000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8111000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6214000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151794000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-146000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1867000
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-694000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	31278000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	40526000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	30905000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16232000
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58425000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-21049000
CY2019	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	-19255000
CY2018	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	67168000
CY2017	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	24333000
CY2017	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	1313000
CY2018	irwd	Purchase Commitment Write Down Sample Supply PurchaseCommitmentWriteDownSampleSupply	390000
CY2017	irwd	Purchase Commitment Write Down Sample Supply PurchaseCommitmentWriteDownSampleSupply	309000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	-3530000
CY2018	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	219000
CY2017	irwd	Gain Or Loss On Sub Leases GainOrLossOnSubLeases	1579000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	165000
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	75000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19590000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17601000
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16080000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31045000
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31310000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2009000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	68893000
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1207000
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	17303000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1046000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3727000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2271000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	806000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-346000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-159000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-702000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-195000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32700000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2678000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7725000
CY2019	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-483000
CY2018	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	542000
CY2017	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-2120000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	875000
CY2019	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-14141000
CY2019	irwd	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12046000
CY2018	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	916000
CY2017	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-1053000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-639000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-82690000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-108040000
CY2019	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	11364000
CY2018	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	11808000
CY2017	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	7287000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10725000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70882000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100753000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3241000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	191354000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99165000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	346890000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7189000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	351000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2803000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	268000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1563000
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	135000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6921000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	97136000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	152868000
CY2019	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-4223000
CY2018	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-8270000
CY2017	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1408000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11144000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	88866000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	151460000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000000
CY2019	irwd	Purchase Of Capped Calls PurchaseOfCappedCalls	25159000
CY2019	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants	3174000
CY2019	irwd	Payments Of Convertible Debt Issuance Costs PaymentsOfConvertibleDebtIssuanceCosts	9048000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13595000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32061000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26370000
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1824000
CY2017	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3234000
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	227338000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	156409000
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	134258000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	235000
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	146250000
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	165000
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	15058000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1185000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	30072000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19835000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1185000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30072000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19835000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1604000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48056000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70542000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132792000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62250000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132792000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177023000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173172000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125736000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2221000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	7676000
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	7056000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132792000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	17584000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	18235000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	20388000
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	664000
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1151000
CY2018	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	2687000
CY2017	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	149000
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	486000
CY2019	irwd	Fixed Assets In Accounts Payable And Accrued Expenses FixedAssetsInAccountsPayableAndAccruedExpenses	1282000
CY2018	irwd	Fixed Assets In Accounts Payable And Accrued Expenses FixedAssetsInAccountsPayableAndAccruedExpenses	439000
CY2017	irwd	Fixed Assets In Accounts Payable And Accrued Expenses FixedAssetsInAccountsPayableAndAccruedExpenses	1136000
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of large unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. On April 1, 2019, the Company completed its tax-free spin-off of its soluble guanylate cyclase (“sGC”) business into a separate publicly traded company, Cyclerion Therapeutics, Inc. (“Cyclerion”).</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists, and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”) and Mexico and to adult men and women suffering from IBS-C in Japan and China. Linaclotide is available, under the trademarked name CONSTELLA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, Allergan plc (together with its affiliates) (“Allergan”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration with Allergan for North America, total net sales of LINZESS in the U.S., as recorded by Allergan, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and Allergan. Allergan also has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “Allergan License Territory”). On a country-by-country and product-by-product basis in the Allergan License Territory, Allergan pays the Company a royalty as a percentage of net sales of products containing linaclotide as an active ingredient. In addition, Allergan has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop and commercialize linaclotide in Japan. In March 2017, Astellas began commercializing LINZESS for the treatment of adults with IBS-C in Japan, and in September 2018, Astellas began commercializing LINZESS for the treatment of adults with chronic constipation in Japan. On August 1, 2019, the Company amended and restated its license agreement with Astellas. Beginning in 2020, the Company will no longer be responsible for the supply of linaclotide active pharmaceutical ingredient (“API”) to Astellas (Note 6). </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2012, the Company and AstraZeneca AB (together with its affiliates) (“AstraZeneca”) entered into a collaboration agreement to co-develop and co-commercialize linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”). In January 2019, the Chinese National Medical Products Administration approved the marketing application for LINZESS for adults with IBS-C in China. As of September 16, 2019, AstraZeneca has the exclusive right to develop, manufacture, and commercialize products containing linaclotide in the AstraZeneca License Territory (Note 6). AstraZeneca launched LINZESS in China in November 2019. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The Company and Allergan are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions. In June 2019, the Company announced positive topline data from its Phase IIIb trial demonstrating the efficacy and safety of LINZESS 290 mcg on the overall abdominal symptoms of bloating, pain and discomfort, in adult patients with IBS-C. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The Company and Allergan are advancing MD-7246, a delayed release formulation of linaclotide, as an oral, intestinal, non-opioid, pain-relieving agent for patients with abdominal pain associated with certain GI diseases. In May 2019, the Company and Allergan announced the initiation of a Phase II clinical trial evaluating the safety and efficacy of MD-7246 in adult patients with IBS with diarrhea (“IBS-D”). </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant, for the potential treatment of refractory gastroesophageal reflux disease (“refractory GERD”). In June 2018, the Company initiated two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with refractory GERD<span style="font-size:12pt;">. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, the Company periodically enters into co-promotion agreements to bolster its salesforce productivity. For example, in April 2019, the Company entered into an agreement with Allergan to continue to perform sales detailing activities for VIBERZI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (eluxadoline) from April 1, 2019 through December 31, 2019. In August 2019, the Company entered into a disease education and promotional agreement with Alnylam Pharmaceuticals, Inc. (“Alnylam”) for Alnylam’s GIVLAARI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (givosiran), an RNAi therapeutic targeting aminolevulinic acid synthase 1, for the treatment of acute hepatic porphyria (“AHP”). GIVLAARI was approved by the U.S. FDA, in December 2019. Under the agreement, the Company performs disease awareness activities related to AHP and sales detailing activities of GIVLAARI.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 6, <i style="font-style:italic;">Collaboration, License, Co-Promotion and Other Commercial Agreements,</i> to these consolidated financial statements. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">On April 1, 2019, Ironwood completed the separation of its sGC business, and certain other assets and liabilities, into Cyclerion (the “Separation”). The Separation was effected by means of a distribution of all of the outstanding shares of common stock, with no par value, of Cyclerion through a dividend of all outstanding shares of Cyclerion’s common stock, to Ironwood’s stockholders of record as of the close of business on March 19, 2019 (Note 3). </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">On June 11, 2019, the Company entered into a non-cancelable operating lease (the “Summer Street Lease”) for approximately 39,000 square feet of office space on the 23<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup> floor of 100 Summer Street, Boston, Massachusetts (the “Summer Street Property”). The Summer Street Property became the Company’s new headquarters in October 2019, replacing its prior headquarters at 301 Binney Street (Note 9). </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company issued $200.0 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2024 (the “2024 Convertible Notes”) and $200.0 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”). The Company received net proceeds of approximately $391.0 million from the sale of the 2024 Convertible Notes and the 2026 Convertible Notes, after deducting fees and expenses of approximately $9.0 million.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The proceeds from the issuance of the 2024 Convertible Notes and the 2026 Convertible Notes were used in August 2019 to pay the cost of associated capped call transactions (the “Capped Calls”) and to repurchase $215.0 million aggregate principal amount of the existing 2.25% Convertible Senior Notes due 2022 (the “2022 Convertible Notes”) and in September 2019 to redeem all of the outstanding principal balance of the 8.375% Notes due 2026 (the “2026 Notes”) (Note 12). The Company retired the 2026 Notes, which had an outstanding aggregate principal balance of approximately $116.5 million, for a redemption price of approximately $123.0 million. During the year ended December 31, 2019, the Company recognized a loss on extinguishment of debt of approximately $31.0 million related to the redemption of the 2026 Notes and the partial repurchase of the 2022 Convertible Notes. These transactions are more fully described in Note 12, <i style="font-style:italic;">Notes Payable</i>, to these consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates. Prior to the year ended December 31, 2019, the Company incurred net losses in each year since its inception in 1998. For the year ended December 31, 2019, the Company recorded net income of approximately $21.5 million. As of December 31, 2019, the Company had an accumulated deficit of approximately $1.6 billion.</p>
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21500000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1600000000
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:14pt;padding-left:10.1pt;text-indent:-10.1pt;margin:2pt 0pt 0pt 0pt;"><b style="font-family:'Times';font-weight:bold;">Reclassifications and Revisions to Prior Period Financial Statements</b></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Times';"> Certain prior period financial statement items have been reclassified to conform to current period presentation. The Company has presented its </span>sGC<span style="font-family:'Times';"> business as discontinued operations in its consolidated financial statements for all periods presented. The historical financial statements and footnotes have been recast accordingly.</span><span style="font-family:'Times';"> </span></p>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue recognition; accounts receivable; inventory valuation and related reserves; useful lives of long-lived assets, impairment of long-lived assets, including its acquired intangible assets and goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation procedures for the issuance and repurchase of convertible notes; valuation of assets and liabilities held for disposition and losses related to discontinued operations; fair value of derivatives; balance sheet classification of notes payable and convertible notes; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	177000000.0
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	173100000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2200000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	7700000
CY2019Q4	irwd	Withdrawal Of Restricted Cash Upon Termination Of Lease WithdrawalOfRestrictedCashUponTerminationOfLease	6400000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000.0
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151800000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in certain types of investments, and requires all investments held by the Company to be at least AA- rated, thereby reducing credit risk exposure.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable, including related party accounts receivable, primarily consist of amounts due under the linaclotide collaboration agreement with Allergan for North America and linaclotide license agreement with Astellas for Japan (Note 6). The Company does not obtain collateral for its accounts receivable. Accounts receivable or payable to or from Allergan and Cyclerion are presented as related party accounts receivable and related party accounts payable, respectively, on the consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The percentages of revenue recognized from significant customers of the Company in the years ended December 31, 2019, 2018 and 2017 as well as the account receivable balances, net of any payables due, at December 31, 2019 and 2018 are included in the following table:</p><p style="font-family:'Times New Roman';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounts<br/>Receivable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaborative Partner:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Allergan (North America and Europe)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Astellas (Japan)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">% </p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">For the years ended December 31, 2019, 2018 and 2017, no additional customers accounted for more than 10% of the Company’s revenue.</p>
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2019	us-gaap	Lease Practical Expedients Package LeasePracticalExpedientsPackage	true
CY2019Q4	us-gaap	Lease Practical Expedient Lessor Single Lease Component LeasePracticalExpedientLessorSingleLeaseComponent	true
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	88300000
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	94900000
CY2019	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2019	us-gaap	Revenue Practical Expedient Initial Application And Transition Completed Contract Use Of Transaction Price At Contract Completion Date RevenuePracticalExpedientInitialApplicationAndTransitionCompletedContractUseOfTransactionPriceAtContractCompletionDate	true
CY2019	us-gaap	Revenue Practical Expedient Initial Application And Transition Nonrestatement Of Modified Contract RevenuePracticalExpedientInitialApplicationAndTransitionNonrestatementOfModifiedContract	true
CY2019	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	0
CY2019	irwd	Number Of Transition Services Agreements NumberOfTransitionServicesAgreements	2
CY2019	irwd	Transitional Services Agreement Initial Term Of Service High End Of Range TransitionalServicesAgreementInitialTermOfServiceHighEndOfRange	P2Y
CY2019	irwd	Transitional Services Agreement Initial Term Of Service Low End Of Range TransitionalServicesAgreementInitialTermOfServiceLowEndOfRange	P1Y
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-116937000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	156023000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152634000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148993000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.14
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.85
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67087000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	64080000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63925000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2019Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2018	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2019	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	108188000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-67168000
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	41020000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	-28909000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	19255000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	31366000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151800000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1146000
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	65000
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	392000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	191000
CY2019Q4	us-gaap	Inventory Net InventoryNet	648000
CY2018	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	0
CY2019	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	0
CY2019Q4	irwd	Number Of Supply Agreements Containing Minimum Purchase Commitments NumberOfSupplyAgreementsContainingMinimumPurchaseCommitments	2
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	10100000
CY2019	irwd	Purchase Commitment Write Down Settlement Amount PurchaseCommitmentWriteDownSettlementAmount	3500000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	16452000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1526000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1512000
CY2019	us-gaap	Lease Cost LeaseCost	19490000
CY2019	us-gaap	Sublease Income SubleaseIncome	300000
CY2019	irwd	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Upon Adoption Of New Accounting Standard Codification RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityUponAdoptionOfNewAccountingStandardCodification	88299000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Modification AdjustmentToRightOfUseAssetLeaseModification	-40427000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Termination AdjustmentToRightOfUseAssetLeaseTermination	34440000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18452000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	18598000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1146000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3128000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3129000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3065000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3126000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	18044000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	31638000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8410000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23228000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22082000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	18736000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	18312000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	18863000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	19365000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	19818000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	22118000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	117212000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22511000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33490000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10082000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25838000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12429000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7652000
CY2018Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	200000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5600000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3900000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6400000
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2973000
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3054000
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2540000
CY2018Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3493000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	11760000
CY2018Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	13867000
CY2019Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1260000
CY2018Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1883000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1421000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1735000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	301000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	873000
CY2019Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	179000
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2885000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10031000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10211000
CY2019Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	30465000
CY2018Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	38001000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000000.0
CY2019Q4	irwd	Other Accrued Liabilities Current Move Activities OtherAccruedLiabilitiesCurrentMoveActivities	900000
CY2019Q4	irwd	Unbilled Inventories UnbilledInventories	600000
CY2019Q4	irwd	Other Accrued Expenses Contracted Services OtherAccruedExpensesContractedServices	200000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10200000
CY2015Q2	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	21100000
CY2019Q3	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	25200000
CY2019Q3	irwd	Debt Instrument Conditional Conversion Repurchase Price Principal Percentage DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage	1
CY2019Q3	irwd	Debt Instrument Default Payment Percentage Of Principal Amount Of Notes Outstanding DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding	0.25
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	153894000
CY2019	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	65000
CY2015Q2	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	21100000
CY2019Q3	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants	3200000
CY2019	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	3000000.0
CY2019Q4	irwd	Number Of Supply Agreements Containing Minimum Purchase Commitments NumberOfSupplyAgreementsContainingMinimumPurchaseCommitments	2
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	0
CY2019Q4	irwd	Number Of Series Of Common Stock NumberOfSeriesOfCommonStock	2
CY2019Q4	irwd	Class Of Warrant Or Right Minimum Percentage Of Beneficial Ownership In Common Stock ClassOfWarrantOrRightMinimumPercentageOfBeneficialOwnershipInCommonStock	0.30
CY2019	irwd	Common Stock Conversion Ratio CommonStockConversionRatio	1
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41082000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30905000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41082000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30905000
CY2019	irwd	Allocated Share Based Compensation Expense Other Modifications AllocatedShareBasedCompensationExpenseOtherModifications	3000000.0
CY2017Q4	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	153900000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4517000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59297000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-39759000
CY2018	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	218000
CY2017	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	34000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1902000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-17121000
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-6117000
CY2019	irwd	Effective Income Tax Rate Reconciliation Disallowed Separation Related Costs EffectiveIncomeTaxRateReconciliationDisallowedSeparationRelatedCosts	4658000
CY2019	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	662000
CY2018	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	8000
CY2019	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	495000
CY2018	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	995000
CY2017	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	1346000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1202000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-494000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	9000
CY2019	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-3324000
CY2018	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	1223000
CY2017	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	2626000
CY2019	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	-290000
CY2018	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	2367000
CY2017	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	1289000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4374000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	7863000
CY2017	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	12290000
CY2019	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	3764000
CY2018	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	250000
CY2017	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	276000
CY2019	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-2563000
CY2018	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	1476000
CY2017	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-232000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7154000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	80684000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-95824000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	265494000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	259450000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	59892000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	60115000
CY2019Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	9952000
CY2018Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	12113000
CY2018Q4	irwd	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	14000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	24401000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	23242000
CY2019Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	48594000
CY2018Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	36423000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6415000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	10867000
CY2019Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	4322000
CY2018Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	7220000
CY2019Q4	irwd	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	22020000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2017	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2018	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2018Q4	irwd	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	5104000
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	25928000
CY2019Q4	irwd	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	6421000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5295000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18867000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	452806000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	459343000
CY2019Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2024 DeferredTaxLiabilitiesConvertibleSeniorNotes2024	7381000
CY2019Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2026 DeferredTaxLiabilitiesConvertibleSeniorNotes2026	10276000
CY2019Q4	irwd	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4905000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	22562000
CY2019Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	430244000
CY2018Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	459343000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	430244000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	459343000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	80700000
CY2019Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	64600000
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	63300000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38551000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24078000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26393000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	51699000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	38551000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	24078000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1400000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	38551000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	24078000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	26393000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53099000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38551000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24078000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53100000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38600000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24100000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53100000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-59284000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	12283000
CY2019	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent	0.75
CY2019	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum	6000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2018	us-gaap	Restructuring Charges RestructuringCharges	14700000
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68730000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102215000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131167000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126301000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428413000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	85663000
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	80638000
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	65280000
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	76709000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	308290000
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4912000
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9294000
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45239000
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1735000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61180000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-21846000
CY2019Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	12283000
CY2019Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	20648000
CY2019Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	47858000
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	58943000
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	20648000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	47858000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
CY2019Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.08
CY2019Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.13
CY2019Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.31
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.38
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.14
CY2019Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.08
CY2019Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.13
CY2019Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.30
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.38
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69155000
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81106000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65686000
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130692000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346639000
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	88438000
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	95783000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	212257000
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	100831000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	497309000
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7276000
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9460000
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5252000
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21488000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43476000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-26559000
CY2018Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-24137000
CY2018Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-151823000
CY2018Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	8373000
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-194146000
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-16585000
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-25243000
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22528000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-43144000
CY2018Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-23866000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-88222000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-49380000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-174351000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-15493000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.18
CY2018Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.16
CY2018Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.99
CY2018Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.05
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.27
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.11
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.17
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.15
CY2018Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.15
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.58
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.85
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2019Q2	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3200000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-31000000.0
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3000000.0
CY2018	us-gaap	Restructuring Charges RestructuringCharges	14700000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151800000
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-8700000

Files In Submission

Name	View Source	Status
0001558370-20-000779-index-headers.html	Edgar Link	pending
0001558370-20-000779-index.html	Edgar Link	pending
0001558370-20-000779.txt	Edgar Link	pending
0001558370-20-000779-xbrl.zip	Edgar Link	pending
ex-10d38.htm	Edgar Link	pending
ex-10d39.htm	Edgar Link	pending
ex-10d4.htm	Edgar Link	pending
ex-21d1.htm	Edgar Link	pending
ex-23d1.htm	Edgar Link	pending
ex-31d1.htm	Edgar Link	pending
ex-31d2.htm	Edgar Link	pending
ex-32d1.htm	Edgar Link	pending
ex-32d2.htm	Edgar Link	pending
ex-4d5.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
irwd-20191231.xsd	Edgar Link	pending
irwd-20191231x10k2b6bd4.htm	Edgar Link	pending
irwd-20191231x10k2b6bd4002.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4003.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4005.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4006.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4007.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4008.jpg	Edgar Link	pending
irwd-20191231x10k2b6bd4_htm.xml	Edgar Link	completed
irwd-20191231_cal.xml	Edgar Link	unprocessable
irwd-20191231_def.xml	Edgar Link	unprocessable
irwd-20191231_lab.xml	Edgar Link	unprocessable
irwd-20191231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R140.htm	Edgar Link	pending
R141.htm	Edgar Link	pending
R142.htm	Edgar Link	pending
R143.htm	Edgar Link	pending
R144.htm	Edgar Link	pending
R145.htm	Edgar Link	pending
R146.htm	Edgar Link	pending
R147.htm	Edgar Link	pending
R148.htm	Edgar Link	pending
R149.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R150.htm	Edgar Link	pending
R151.htm	Edgar Link	pending
R152.htm	Edgar Link	pending
R153.htm	Edgar Link	pending
R154.htm	Edgar Link	pending
R155.htm	Edgar Link	pending
R156.htm	Edgar Link	pending
R157.htm	Edgar Link	pending
R158.htm	Edgar Link	pending
R159.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R160.htm	Edgar Link	pending
R161.htm	Edgar Link	pending
R162.htm	Edgar Link	pending
R163.htm	Edgar Link	pending
R164.htm	Edgar Link	pending
R165.htm	Edgar Link	pending
R166.htm	Edgar Link	pending
R167.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2019 Q4 Form 10-K Financial Statement

#000155837020000779 Filed on February 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2019 Q4 Form 10-K Financial Statement

#000155837020000779 Filed on February 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd